Clinical Trials Logo

Clinical Trial Summary

Introduction OHSS still remains a complication of assisted reproduction treatments. hCG administration to trigger final oocyte maturation will release vascular mediators, being VEGF and other proteins such as VE-Cadherin or Angiopoietin- 2. It has been shown that replacing hCG by GnRH agonists will induce a very short endogenous LH peak, potent enough to induce final oocyte maturation but no OHSS will develop. The investigators examined VEGF, VE-Cadherin and Angiopoietin-2 modulation by hCG as well as GnRH agonists in oocyte donors undergoing controlled ovarian stimulation.


Clinical Trial Description

Material and Methods Between June and December of 2008 we evaluated 90 egg donors. They underwent COH with 150 IU rFSH as starting dose, we separated them in 3 groups (n:30 each): Groups 1 and 2 received a 0.25mg daily dose of GnRH antagonist when a follicle 14mm in diameter was observed. hCG 250g was given to group 1 while group 2 received triptorelin 0.2mg when leading two follicles were 17mm. Group 3 was stimulated with standard long protocol, hCG was given following similar criteria.

Blood was collected the day of hCG/aGnRH administration as well as the day of egg retrieval, and follicular fluid from the first two mature follicles was also frozen. We collected granulosa cells (GC) of 10 patients of each group as well Levels of VEGF, sVE-Cadherin an Angiopietin 2 were determined by ELISA in serum and in follicular fluid.

Results were analyzed via ANOVA.Data are expressed as mean± SEM. A significant difference was defined as p< 0.05. ;


Study Design


Related Conditions & MeSH terms

  • Vascular Endothelial Growth Factor Overexpression

NCT number NCT00848185
Study type Observational
Source IVI Madrid
Contact
Status Completed
Phase
Start date June 2008
Completion date March 2009

See also
  Status Clinical Trial Phase
Completed NCT02168322 - Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels N/A
Terminated NCT04991350 - Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema Phase 4
Completed NCT04970251 - Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma N/A
Completed NCT04674254 - Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy Phase 4
Completed NCT02447679 - Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence Phase 2
Recruiting NCT03648814 - Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT N/A
Completed NCT02708537 - Effect of Plasma Rich in Growth Factors on Semen Quality